Pros and cons of treating murine myasthenia gravis with anti-C1q antibody

Tuzun E., LI J., SAINI S. S., YANG H., CHRISTADOSS P.

JOURNAL OF NEUROIMMUNOLOGY, vol.182, pp.167-176, 2007 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 182
  • Publication Date: 2007
  • Doi Number: 10.1016/j.jneuroim.2006.10.014
  • Journal Name: JOURNAL OF NEUROIMMUNOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.167-176
  • Keywords: C1q, classical complement pathway, myasthenia gravis, autoimmunity, EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS, CIRCULATING IMMUNE-COMPLEXES, T-CELL PROLIFERATION, C1 INHIBITOR, COMPLEMENT INHIBITOR, GENETIC-EVIDENCE, MOTOR ENDPLATE, MICE, C3, PATHOGENESIS
  • Istanbul University Affiliated: Yes

Abstract

To test the feasibility of classical complement pathway manipulation in experimental autoimmune myasthenia gravis (EAMG) treatment, C57BL/6 (B6) and RIIIS/J mice with EAMG were treated with 10 mu g or 100 mu g of anti-C1q Ab or isotype Ab. Treatment with 10 mu g anti-C1q Ab significantly reduced the clinical severity, decreased lymph node cell IL-6 production and T cell populations. Conversely, administration of 100 mu g anti-C1q Ab caused harmful side effects such as increased serum anti-acetylcholine receptor antibody, immune complex, C3 and lymph node B cell levels and kidney C3 and IgG deposits, which reduced the treatment efficacy. (c) 2006 Elsevier B.V. All rights reserved.